Social Functioning Trajectories of Young First-Episode Psychosis Patients with and without Cannabis Misuse: A 30-Month Follow-Up Study

The aim of the study was to investigate trajectories of social functioning in young people with first-episode psychosis (FEP) with and without cannabis misuse using a secondary analysis of data from the Episode-II trial. Forty-two young people with FEP and comorbid cannabis use disorder were compared with 39 young people with FEP but without a cannabis use disorder. Social functioning was assessed every 6 months during a 30-month follow-up. Multilevel linear growth curve modeling was used to compare the social functioning trajectories over time for those with and without cannabis misuse. Cannabis misuse was not associated with social functioning at baseline assessment. Over a 30-month follow-up, FEP patients without cannabis disorder showed significant improvements in their social functioning, whereas patients with cannabis misuse at baseline displayed no such improvement. Patients with and without cannabis misuse differed significantly in their levels of social functioning after 24 months. Similar results were obtained after adjusting for potential confounders (i.e., age, gender, negative symptoms, premorbid functioning, DSM-IV diagnoses, baseline social functioning and other substance use). In the context of a specialized early intervention service, patients with cannabis misuse at baseline did not attain the improvements in social outcomes observed in their counterparts without cannabis misuse. There is a need to develop effective interventions to reduce cannabis misuse to ultimately improve social outcomes in young people with psychosis.

[1]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[2]  Andrés Martin,et al.  Is the party over? Cannabis and juvenile psychiatric disorder: the past 10 years. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[3]  J. Addington,et al.  Outcome of a first episode of psychosis in adolescence: a 2-year follow-up , 2005, Psychiatry Research.

[4]  P. McGorry,et al.  Predictors of Adherence to Cognitive-Behavioural Therapy in First-Episode Psychosis , 2009, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[5]  J. Addington,et al.  Patterns, predictors and impact of substance use in early psychosis: a longitudinal study , 2007, Acta psychiatrica Scandinavica.

[6]  B. Xie,et al.  Intrinsic motivation, neurocognition and psychosocial functioning in schizophrenia: Testing mediator and moderator effects , 2008, Schizophrenia Research.

[7]  D S Rae,et al.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. , 1990, JAMA.

[8]  R. Ali,et al.  Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site. , 2005, Drug and alcohol review.

[9]  P. McGorry,et al.  Family outcomes from a randomized control trial of relapse prevention therapy in first-episode psychosis. , 2010, Journal of Clinical Psychiatry.

[10]  A. Bellack,et al.  A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. , 2006, Archives of general psychiatry.

[11]  R. Liberman,et al.  Symptom monitoring in the rehabilitation of schizophrenic patients. , 1986, Schizophrenia bulletin.

[12]  N. Andreasen.  Scale for the Assessment of Negative Symptoms , 2014 .

[13]  H. Smid,et al.  Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial. , 2012, The Journal of clinical psychiatry.

[14]  C. Arango,et al.  Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use , 2009, Schizophrenia bulletin.

[15]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[16]  M. First,et al.  Structured clinical interview for DSM-IV axis II personality disorders : SCID-II , 1997 .

[17]  J. Miettunen,et al.  Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. , 2010, Schizophrenia bulletin.

[18]  A. Mann,et al.  Outcome of common mental disorders in Harare, Zimbabwe , 1998, British Journal of Psychiatry.

[19]  B. Crespo-Facorro,et al.  Prognostic value of cognitive functioning for global functional recovery in first-episode schizophrenia , 2009, Psychological Medicine.

[20]  M. Rubio‐Stipec,et al.  The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. , 2002, Addiction.

[21]  H. Goldman,et al.  Revising axis V for DSM-IV: a review of measures of social functioning. , 1992, The American journal of psychiatry.

[22]  A. Malla,et al.  Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. , 2010, Schizophrenia bulletin.

[23]  Leslie G. Portney Dpt PhD Fapta,et al.  Foundations of Clinical Research: Applications to Practice , 2015 .

[24]  S M Montgomery,et al.  Depressive symptoms in acute schizophrenia. , 1979, Progress in neuro-psychopharmacology.

[25]  T. George,et al.  The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis , 2011, Schizophrenia Research.

[26]  J. Hoenig,et al.  Statistical Practice The Abuse of Power: The Pervasive Fallacy of Power Calculations for Data Analysis , 2001 .

[27]  David Castle,et al.  A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients. , 2009, The Journal of clinical psychiatry.

[28]  M. Birchwood,et al.  Early intervention in psychosis: the critical‐period hypothesis , 1998, British Journal of Psychiatry.

[29]  P. McGorry,et al.  Enhancing Treatment Fidelity in Psychotherapy Research: Novel Approach to Measure the Components of Cognitive Behavioural Therapy for Relapse Prevention in First-Episode Psychosis , 2008, The Australian and New Zealand journal of psychiatry.

[30]  S. Eack,et al.  Characterizing the longitudinal patterns of substance use among individuals diagnosed with serious mental illness after psychiatric hospitalization. , 2013, Addiction.

[31]  P. McGorry,et al.  Randomized controlled trial of a cannabis‐focused intervention for young people with first‐episode psychosis , 2006, Acta psychiatrica Scandinavica.

[32]  R. Emsley,et al.  Does change in cannabis use in established psychosis affect clinical outcome? , 2013, Schizophrenia bulletin.

[33]  N. Andreasen.  Scale for the Assessment of Negative Symptoms (SANS) and Scale for the Assessment of Positive Symptoms (SAPS) 1982 , 2007 .

[34]  Peter B. Jones,et al.  Effects of cannabis use on outcomes of psychotic disorders: systematic review , 2008, British Journal of Psychiatry.

[35]  R. Wyatt,et al.  Measurement of premorbid adjustment in chronic schizophrenia. , 1982, Schizophrenia bulletin.

[36]  M. Nordentoft,et al.  Intervention efficacy in trials targeting cannabis use disorders in patients with comorbid psychosis systematic review and meta-analysis. , 2014, Current pharmaceutical design.

[37]  P. McGorry,et al.  The reliability and validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in first-episode psychosis. , 2009, Addictive behaviors.

[38]  M. Lambert,et al.  Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis , 2012, European Psychiatry.

[39]  J. Gleeson,et al.  Longitudinal relationship between expressed emotion and cannabis misuse in young people with first-episode psychosis , 2015, European Psychiatry.

[40]  E. Bora,et al.  The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. , 2012, Schizophrenia bulletin.

[41]  W. Hall,et al.  The effects of adolescent cannabis use on educational attainment: a review. , 2000, Addiction.

[42]  Mario Alvarez-Jimenez,et al.  A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up. , 2013, Schizophrenia bulletin.

[43]  N. Bolger,et al.  Intensive Longitudinal Methods: An Introduction to Diary and Experience Sampling Research , 2013 .

[44]  M. Nordentoft,et al.  Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: a 5-year follow-up study of patients in the OPUS trial , 2013, Psychological Medicine.

[45]  George Mendelson,et al.  Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) , 2009 .

[46]  Peter B. Jones,et al.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review , 2007, The Lancet.

[47]  D. Heisey,et al.  The Abuse of Power , 2001 .

[48]  A. Hill,et al.  Wechsler Test of Adult Reading , 2017 .

[49]  R. Kotov,et al.  Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. , 2010, The American journal of psychiatry.